Dizal (Jiangsu) Pharmaceutical Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Zhang Xiaolin

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	1.8%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	3.7yrs

Actualizaciones recientes de la dirección

Recent updates

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192) Analysts Just Slashed This Year's Revenue Estimates By 12%

May 02

Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?

Apr 30

CEO

Zhang Xiaolin (59 yo)

no data

Permanencia

CN¥11,727,700

Compensación

Dr. Zhang Xiaolin Ph.D. is General Manager and Chairman of Dizal (Jiangsu) Pharmaceutical Co., Ltd. and served as its Chief Scientist. Dr. Xiaolin joined the Dizal (Jiangsu) Pharmaceutical Co., Ltd.in 201...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Zhang Xiaolin	GM & Chairman	no data	CN¥11.73m	1.76% CN¥ 285.9m
Guanshan Zhu	Independent Director	3.7yrs	CN¥100.00k	sin datos
Simon Dazhong Lu	Director	7.3yrs	sin datos	sin datos
Rodolphe Peter Andre Grepinet	Director	7.3yrs	sin datos	sin datos
Jiang Bin	Independent Director	3.7yrs	CN¥100.00k	sin datos
Wang Xuegong	Independent Director	3.7yrs	CN¥100.00k	sin datos
Zhang Xin	Independent Director	3.7yrs	CN¥100.00k	sin datos
Dong Weiwen	Chairman of the Supervisory Board	no data	sin datos	sin datos
Yuan Sun	Supervisor	no data	sin datos	sin datos
Xiaojing Kang	Employee Supervisor	2.3yrs	sin datos	0.0041% CN¥ 664.7k

3.7yrs

Permanencia media

51yo

Promedio de edad

Junta con experiencia: La junta directiva de 688192 se considera experimentada (3.6 años de antigüedad promedio).

Dizal (Jiangsu) Pharmaceutical Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Dizal (Jiangsu) Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Insufficient new directors

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Consensus revenue estimates decrease by 12%

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192) Analysts Just Slashed This Year's Revenue Estimates By 12%

New major risk - Financial position

Dizal (Jiangsu) Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?

New minor risk - Financial position

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces Two Abstracts Featuring the Latest Data on Sunvozertinib in Non-Small Cell Lung Cancer

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Dizal's Sunvozertinib for the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

New major risk - Revenue and earnings growth

Now 21% undervalued

Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine

Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH

Consensus EPS estimates fall by 13%

New major risk - Share price stability

Dizal Announces Latest Research Findings on the Efficacy and Safety of Sunvozertinib in Treatment-Naive Patients

Insufficient new directors

Dizal Pharmaceutical Receives Priority Review by China NMPA for the Treatment of r/r PTCL

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL

Dizal Pharmaceutical Announces Clinical Results of Golidocitinib Published in Annals of Oncology

New major risk - Revenue and earnings growth

Dizal Will Present the Results of Molecular Analysis on EGFR Exon20ins Mutations in Tumor Tissue and Plasma ctDNA

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Presents Compelling Data of Its Robust Oncology Portfolio At the 2023 American Society of Clinical Oncology Annual Meeting

Price target increased by 11% to CN¥56.42

Dizal Announces Center for Drug Evaluation Acceptance of New Drug Application for Sunvozertinib for Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations

Less than half of directors are independent

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces Sunvozertinib Meets Primary Endpoint in Its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces Sunvozertinib Meets Primary Endpoint in Its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO

Dizal Demonstrates Clinical Update for Sunvozertinib (DZD9008) in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 WCLC

Dizal Pharmaceutical Announces Pre-Clinical and Clinical Results of Sunvozertinib (DZD9008) Published in Cancer Discovery

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Dizal Pharmaceutical Receives U.S. FDA Fast Track Designation for Dzd4205 for the Treatment of Refractory or Relapsed Peripheral T-Cell Lymphoma

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Dizal Pharmaceutical's DZD9008 (Sunvozertinib) for the Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

CEO

Permanencia

Compensación

Miembros de la Junta

Permanencia media

Promedio de edad